Medical Marketing and Media - Bextra woes boost rivals as treatment options narrow
Monday, January 5th, 2009THE PAINKILLER Mobic saw sharp gains in new users in the days following Pfizer’s withdrawal of COX-2 drug Bextra.
In the week ending April 8, nearly 25 percent of former Bextra patients switched to Mobic, which is jointly marketed by Abbott Laboratories and Boehringer Ingelheim, according to data from Verispan’s Vector One.
Bear Stearns analyst Rick Wise said in published repo…
